Brokers Set Expectations for Hepion Pharmaceuticals, Inc.’s FY2022 Earnings (NASDAQ:HEPA)

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPAGet Rating) – Cantor Fitzgerald raised their FY2022 earnings estimates for Hepion Pharmaceuticals in a report released on Wednesday, May 18th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($0.49) per share for the year, up from their previous estimate of ($0.52). Cantor Fitzgerald currently has a “Overweight” rating and a $3.50 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Hepion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 29th. Brookline Capital Management restated a “buy” rating on shares of Hepion Pharmaceuticals in a research report on Wednesday, January 26th.

HEPA stock opened at $0.75 on Monday. Hepion Pharmaceuticals has a 12 month low of $0.61 and a 12 month high of $2.32. The company has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.11.

Large investors have recently bought and sold shares of the company. State Street Corp grew its stake in Hepion Pharmaceuticals by 8.1% in the 1st quarter. State Street Corp now owns 348,910 shares of the company’s stock valued at $450,000 after acquiring an additional 26,194 shares during the last quarter. Renaissance Technologies LLC grew its stake in Hepion Pharmaceuticals by 151.7% in the 1st quarter. Renaissance Technologies LLC now owns 126,600 shares of the company’s stock valued at $163,000 after acquiring an additional 76,300 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Hepion Pharmaceuticals by 204.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 35,139 shares of the company’s stock valued at $40,000 after acquiring an additional 23,584 shares during the last quarter. Virtu Financial LLC acquired a new stake in Hepion Pharmaceuticals in the 4th quarter valued at about $57,000. Finally, Envestnet Asset Management Inc. grew its stake in Hepion Pharmaceuticals by 87.5% in the 4th quarter. Envestnet Asset Management Inc. now owns 72,027 shares of the company’s stock valued at $82,000 after acquiring an additional 33,609 shares during the last quarter. 11.57% of the stock is currently owned by institutional investors and hedge funds.

About Hepion Pharmaceuticals (Get Rating)

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.

Recommended Stories

Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.